Evidence map›Paper›PMID 25654979›Full record

ArticleCirculation research2015

Direct evaluation of myocardial viability and stem cell engraftment demonstrates salvage of the injured myocardium.

Paul J Kim, Morteza Mahmoudi, Xiaohu Ge, Yuka Matsuura, Ildiko Toma, Scott Metzler, Nigel G Kooreman, John Ramunas, Colin Holbrook, Michael V McConnell and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Manganese-enhanced TScientific reports · 2020
    Article
  14. Utilization of Human Induced Pluripotent Stem Cells for Cardiac Repair.Frontiers in cell and developmental biology · 2020
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Manganese-Enhanced TContrast media & molecular imaging · 2018
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Paul J KimFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Morteza MahmoudiFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Xiaohu GeFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Yuka MatsuuraFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Ildiko TomaFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Scott MetzlerFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Nigel G KooremanFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
John RamunasFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Colin HolbrookFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Michael V McConnellFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Helen BlauFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Phillip HarnishFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Eric RulifsonFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.).
Phillip C YangFrom the Division of Cardiovascular Medicine, Department of Medicine, Stanford University Medical Center, CA (P.J.K., M.M., X.G., Y.M., I.T., S.M., N.G.K., M.V.M., E.R., P.C.Y.); Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (J.R., C.H., H.B.); and Eagle Vision Pharmaceutical Corporation, Exton, PA (P.H.). phillip@stanford.edu.
Baxter (United States) · USStanford University · US

Funding

Telomere extension using nucleoside-modified mRNA and exosomes as a novel therapeR01AR063963 · NIAMS · STANFORD UNIVERSITY · PI BLAU, HELEN M · 2012 to 2016
$4.3M
Multi-Disciplinary Training Program in Cardiovascular Imaging at StanfordT32EB009035 · NIBIB · STANFORD UNIVERSITY · PI Koen Nieman, John M. Pauly · 2008 to 2026
$4.3M
Cell Characterization and Imaging for Regenerative Therapies in Ischemic DiseasesUM1HL113456 · NHLBI · STANFORD UNIVERSITY · PI YANG, PHILLIP CHUNG-MING · 2012 to 2018
$3.3M
Role of Non-muscle MLCK in Neutrophil-mediated Acute Lung InjuryR01HL095716 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI XU, JINGSONG · 2009 to 2013
$2.1M
NHLBI NIH HHS 1R01HL095716-01NHLBI NIH HHS 5UM1 HL113456-0NHLBI NIH HHS R01 HL095716NHLBI NIH HHS UM1 HL113456NIAMS NIH HHS R01AR063963NIBIB NIH HHS T32 EB009035
6 · The paper itself

Abstract

rationaleThe mechanism of functional restoration by stem cell therapy remains poorly understood. Novel manganese-enhanced MRI and bioluminescence reporter gene imaging were applied to follow myocardial viability and cell engraftment, respectively. Human-placenta-derived amniotic mesenchymal stem cells (AMCs) demonstrate unique immunoregulatory and precardiac properties. In this study, the restorative effects of 3 AMC-derived subpopulations were examined in a murine myocardial injury model: (1) unselected AMCs, (2) ckit(+)AMCs, and (3) AMC-derived induced pluripotent stem cells (MiPSCs).

objectiveTo determine the differential restorative effects of the AMC-derived subpopulations in the murine myocardial injury model using multimodality imaging. METHODS AND

resultsSCID (severe combined immunodeficiency) mice underwent left anterior descending artery ligation and were divided into 4 treatment arms: (1) normal saline control (n=14), (2) unselected AMCs (n=10), (3) ckit(+)AMCs (n=13), and (4) MiPSCs (n=11). Cardiac MRI assessed myocardial viability and left ventricular function, whereas bioluminescence imaging assessed stem cell engraftment during a 4-week period. Immunohistological labeling and reverse transcriptase polymerase chain reaction of the explanted myocardium were performed. The unselected AMC and ckit(+)AMC-treated mice demonstrated transient left ventricular functional improvement. However, the MiPSCs exhibited a significantly greater increase in left ventricular function compared with all the other groups during the entire 4-week period. Left ventricular functional improvement correlated with increased myocardial viability and sustained stem cell engraftment. The MiPSC-treated animals lacked any evidence of de novo cardiac differentiation.

conclusionThe functional restoration seen in MiPSCs was characterized by increased myocardial viability and sustained engraftment without de novo cardiac differentiation, indicating salvage of the injured myocardium.

Indexed as

Mesenchymal Stem Cell TransplantationMultimodal ImagingAnimalsCell SeparationCell SurvivalCoronary StenosisDisease Models, AnimalFemaleGene Expression ProfilingGenes, ReporterGraft SurvivalHeterograftsHumansInduced Pluripotent Stem CellsLigationLuminescent MeasurementsManganeseProto-Oncogene Proteins c-kitmagnetic resonance imagingmolecular imagingmultimodal imaging

Identifiers

PMID25654979
PMCPMC4380765
OpenAlexW2104560001

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.